| Ensartinib studied in …STUDIED_INderived24 of 24show fewer |
|---|
| → studied in | NCT04837716Phase 1 · active not recruiting Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer · 24 trials list this drug (15 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155620Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · 24 trials list this drug (15 active) | — | — | Hepatoblastoma,Malignant Germ Cell Tumor,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03213652Phase 2 · active not recruiting Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) · 24 trials list this drug (15 active) | — | — | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor,Hepatoblastoma,Malignant Germ Cell Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03420508Phase 2 · active not recruiting Treating Patients With Melanoma and ALK Alterations With Ensartinib · 24 trials list this drug (15 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05491811Phase 2 · active not recruiting Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737994Phase 2 · terminated Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer · 24 trials list this drug (15 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563999Phase 2 · recruiting Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · 24 trials list this drug (15 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07448116Phase 1/Phase 2 · recruiting Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. · 24 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07235306Phase 2 · not yet recruiting Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06955325Phase 3 · not yet recruiting Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06785584Phase 4 · not yet recruiting Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study · 24 trials list this drug (15 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06779539Phase 2 · not yet recruiting Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06780839Phase 2 · not yet recruiting Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06762327Phase 2 · not yet recruiting Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer · 24 trials list this drug (15 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05341583Phase 3 · unknown Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05241028Phase 2 · recruiting Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02959619Phase 1 · completed Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK · 24 trials list this drug (15 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03574402Phase 2 · unknown Phase II Umbrella Study Directed by Next Generation Sequencing · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04146571available Expanded Access to Ensartinib for Participants With ALK+ NSCLC · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02898116Phase 1/Phase 2 · completed Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer · 24 trials list this drug (15 active) | — | — | Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05380024Phase 2 · unknown A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498064recruiting A Real World Study of Ensartinib in Advanced ALK-positive NSCLC · 24 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05178511Phase 2 · unknown Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance · 24 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03536481Phase 1 · completed Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers · 24 trials list this drug (15 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |